Safety And Efficacy of Low Dose Oral Anticoagulants And Aspirin Therapy
Completed
Yasser Elnahas
Phase 3
2010-02-01
A prospective, randomized, longitudinal, open label, parallel group clinical trial was
designed to compare the proportions of failure to reach INR target 2.5-3.5 with either: small
dose warfarin (<5 mg/day) or phenindione (<100 mg/day), in high-risk pregnant and
non-pregnant patients with bileaflet mechanical heart valve prosthesis.
Therapeutic Equivalence Between Branded and Generic WARFArin Tablets in Brazil
Completed
Fundação de Amparo à Pesquisa do Estado de São Paulo
Phase 4
2014-08-01
The purpose of this study is to assess whether the switch from branded to generic warfarin or
between different generic warfarin tablets may cause fluctuation in the results of
coagulation tests (International Normalized Rate, acronym INR) in patients, thus predisposing
them to unnecessary risks.
Therapeutic Equivalence Between Branded and Generic WARFArin Tablets in Brazil
Completed
Federal University of São Paulo
Phase 4
2014-08-01
The purpose of this study is to assess whether the switch from branded to generic warfarin or
between different generic warfarin tablets may cause fluctuation in the results of
coagulation tests (International Normalized Rate, acronym INR) in patients, thus predisposing
them to unnecessary risks.
Edoxaban Compared to Standard Care After Heart Valve Replacement Using a Catheter in Patients With Atrial Fibrillation (ENVISAGE-TAVI AF)
Completed
Chiltern International Inc.
Phase 3
2017-03-21
When the upper chambers of a person's heart receive irregular electrical signals it causes
abnormal rhythm in the heart beat. This is called atrial fibrillation.
Atrial fibrillation increases the chance of having a heart attack or stroke. Some patients
also get new heart valves using a catheter.
Often doctors give patients a medicine called a vitamin K antagonist (VKA), because it is
considered the standard care. This study will see how edoxaban compares to VKA in patients
who got a new heart valve by using a catheter.
The study will compare the two drugs for up to three years after heart valve replacement,
looking at the drug's overall side effects (called adverse events) and major bleeding.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
